Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy.

Fredrick B. Hagemeister

Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy.

Fredrick B. Hagemeister

Lymphoma-Myeloma

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Therapy with rituximab is the most important advance in the treatment of lymphomas since the development of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). Rituximab has single-agent activity in all types of B-cell lymphomas, including indolent and aggressive disease. For large-cell lymphomas, rituximab plus chemotherapy represents a significant advance over chemotherapy alone without significant added toxicity. Some studies report positive results using the antibody to treat other lymphomas. CHOP plus rituximab has become the standard of care.

Original language	English (US)
Pages (from-to)	120-125
Number of pages	6
Journal	Clinical advances in hematology & oncology : H&O
Volume	1
Issue number	2
State	Published - Feb 2003

ASJC Scopus subject areas

Hematology
Oncology

Cite this

@article{51b60f6391c64e0f92da63478e7b2736,

title = "Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy.",

abstract = "Therapy with rituximab is the most important advance in the treatment of lymphomas since the development of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). Rituximab has single-agent activity in all types of B-cell lymphomas, including indolent and aggressive disease. For large-cell lymphomas, rituximab plus chemotherapy represents a significant advance over chemotherapy alone without significant added toxicity. Some studies report positive results using the antibody to treat other lymphomas. CHOP plus rituximab has become the standard of care.",

author = "Hagemeister, \{Fredrick B.\}",

note = "Copyright: This record is sourced from MEDLINE{\textregistered}/PubMed{\textregistered}, a database of the U.S. National Library of Medicine",

year = "2003",

month = feb,

language = "English (US)",

volume = "1",

pages = "120--125",

journal = "Clinical advances in hematology \& oncology : H\&O",

issn = "1543-0790",

publisher = "Millennium Medical Publishing, Inc.",

number = "2",

}

TY - JOUR

T1 - Rituximab and chemotherapy for aggressive lymphomas

T2 - a significant advance in therapy.

AU - Hagemeister, Fredrick B.

N1 - Copyright: This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

PY - 2003/2

Y1 - 2003/2

N2 - Therapy with rituximab is the most important advance in the treatment of lymphomas since the development of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). Rituximab has single-agent activity in all types of B-cell lymphomas, including indolent and aggressive disease. For large-cell lymphomas, rituximab plus chemotherapy represents a significant advance over chemotherapy alone without significant added toxicity. Some studies report positive results using the antibody to treat other lymphomas. CHOP plus rituximab has become the standard of care.

AB - Therapy with rituximab is the most important advance in the treatment of lymphomas since the development of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). Rituximab has single-agent activity in all types of B-cell lymphomas, including indolent and aggressive disease. For large-cell lymphomas, rituximab plus chemotherapy represents a significant advance over chemotherapy alone without significant added toxicity. Some studies report positive results using the antibody to treat other lymphomas. CHOP plus rituximab has become the standard of care.

UR - https://www.scopus.com/pages/publications/33644621813

UR - https://www.scopus.com/pages/publications/33644621813#tab=citedBy

M3 - Review article

C2 - 16224391

AN - SCOPUS:33644621813

SN - 1543-0790

VL - 1

SP - 120

EP - 125

JO - Clinical advances in hematology & oncology : H&O

JF - Clinical advances in hematology & oncology : H&O

IS - 2

ER -

Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy.

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this